Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Relief of tension-type headache symptoms (FDA-approved),Treatment of migraine headache (off-label)
Management of moderate to moderately severe pain,Acute pain,Chronic pain
1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.
1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).
Butalbital: 35-50 hours; Aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours at low doses, 15-30 hours at high doses; Caffeine: 3-7 hours; Codeine: 2.5-4 hours, morphine: 1.5-3.5 hours. Clinical context: Butalbital's long half-life contributes to prolonged sedation and risk of accumulation with repeated dosing.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment or overdose); Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release); Clinical context: Terminal half-life of oxycodone may be prolonged in elderly or patients with renal/hepatic impairment.
Butalbital: hepatic via CYP2C19 and other CYP enzymes, partly excreted unchanged; aspirin: hydrolyzed to salicylate, conjugated in liver; caffeine: hepatic via CYP1A2 (major), CYP2E1, and CYP3A4; codeine: hepatic via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and glucuronidation.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP450 (CYP2E1, CYP3A4) to toxic NAPQI. Oxycodone: hepatic via CYP3A4 (major) and CYP2D6 (minor) to active metabolites (noroxycodone, oxymorphone).
Codeine and its metabolites (morphine, codeine-6-glucuronide, norcodeine) are primarily excreted renally (>90%). Aspirin (acetylsalicylic acid) is hydrolyzed to salicylic acid, which is eliminated renally (75% as salicyluric acid, 10% as salicylic acid, 15% as other metabolites). Caffeine is largely metabolized in the liver and excreted renally (<3% unchanged). Butalbital is eliminated renally as metabolites and unchanged drug (about 60-70% as metabolites, 30-40% unchanged). Biliary/fecal elimination is minimal for all components.
Acetaminophen: renal excretion of metabolites (glucuronide 45-55%, sulfate 20-30%, cysteine and mercapturate conjugates 5-10%) and unchanged drug (<5%); Oxycodone: renal excretion of unchanged drug (approximately 10-19%) and metabolites (noroxycodone, oxymorphone, and their glucuronides) (total renal elimination ~60-87%); fecal elimination of Oxycodone is minimal (<10%).
Butalbital: 20-30% (albumin); Aspirin: dose-dependent, 50-80% to albumin; Caffeine: 25-35% (albumin); Codeine: 20-25% (albumin).
Acetaminophen: 20-30% (albumin); Oxycodone: 45-50% (albumin).
Butalbital: 0.5-0.6 L/kg; Aspirin: 0.15-0.2 L/kg; Caffeine: 0.6-1.0 L/kg; Codeine: 3-6 L/kg. Clinical meaning: High Vd for codeine indicates extensive tissue distribution.
Acetaminophen: 0.9-1.0 L/kg (suggests distribution into total body water); Oxycodone: 2.6-4.0 L/kg (suggests extensive tissue distribution).
Oral: Butalbital ~90%; Aspirin 80-100% (first-pass hydrolysis to salicylic acid); Caffeine ~100%; Codeine ~60-90% (first-pass metabolism to morphine).
Acetaminophen: Oral 85-90%; Oxycodone: Oral 60-87% (first-pass metabolism), Rectal (oxycodone suppository) ~60-80%.
Cr Cl 10-50 m L/min: Administer at 75% of usual dose every 6 hours; Cr Cl <10 m L/min: Administer at 50% of usual dose every 6 hours.
e GFR 30-60 m L/min: start with 50% of usual dose, increase cautiously; e GFR <30 m L/min: start with 25% of usual dose, extend dosing interval to every 8-12 hours; avoid in dialysis due to oxycodone accumulation.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: start with 50% of usual dose, maximum acetaminophen 2000 mg/day; Child-Pugh C: contraindicated.
Not recommended for children under 12 years; for adolescents 12-18 years: 1 capsule orally every 4 hours as needed, not to exceed 4 capsules per day.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) with acetaminophen 10-15 mg/kg/dose every 4-6 hours; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day).
Initiate at lowest effective dose; consider reducing dose by 50% and extending interval to every 6 hours due to increased risk of respiratory depression, renal impairment, and aspirin-induced gastrointestinal bleeding.
Start with lowest dose (e.g., half of adult dose), titrate slowly; avoid in patients with impaired renal/hepatic function or those at risk for falls; monitor for respiratory depression and constipation.
Risk of medication overuse headache; codeine: risk of addiction, abuse, misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; CYP3A4 interaction with benzodiazepines or other CNS depressants.
Risk of Reye's syndrome with aspirin in children/viral illness; avoid exceeding recommended dosage due to rebound headache; GI bleeding risk with aspirin; opioid-induced respiratory depression, misuse, abuse, addiction; codeine use in children post-tonsillectomy/adenoidectomy; impaired alertness; risk of serotonin syndrome with serotonergic drugs; barbiturate dependence; caffeine withdrawal headache; hepatic/renal impairment; co-administration with alcohol or CNS depressants.
Addiction, abuse, misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; hepatotoxicity (acetaminophen); interactions with CNS depressants; elderly or debilitated patients; renal impairment; severe hypotension; adrenal insufficiency; use in patients with head injury.
Hypersensitivity to any component; pediatric patients with chickenpox or influenza-like illness (aspirin); significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; breastfeeding (codeine); concurrent use with MAOIs or within 14 days; porphyria (barbiturates).
Hypersensitivity to acetaminophen or oxycodone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction (e.g., paralytic ileus); severe hepatic impairment; concurrent use with MAOIs or within 14 days.
Avoid alcohol. High-fat meals may delay absorption. Avoid excessive caffeine intake from diet (coffee, tea, soda) to prevent additive stimulation. Maintain adequate hydration to reduce salicylate renal toxicity risk.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid grapefruit products. High-fat meals may delay absorption of oxycodone. Maintain adequate hydration to prevent constipation.
First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some studies. Second trimester: Risk of miscarriage with NSAIDs; codeine not clearly associated. Third trimester: Aspirin and codeine associated with premature closure of ductus arteriosus, oligohydramnios, neonatal hemorrhage, and respiratory depression; butalbital may cause neonatal withdrawal. Overall: Combination product has multiple teratogenic components; avoid in pregnancy unless benefit outweighs risk.
Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; respiratory depression at delivery. No specific human data for combination; extrapolated from individual components.
Aspirin and caffeine are excreted in breast milk; codeine is excreted in low amounts but may cause CNS depression in infants, especially in CYP2D6 ultrarapid metabolizers. Butalbital is excreted in low amounts. M/P ratio: Not established for this combination; codeine M/P ratio approximately 0.2-0.4. Use with caution; monitor infant for sedation, respiratory depression, poor feeding.
Acetaminophen: Compatible; M/P ratio ~1.0 (low transfer). Oxycodone: Low levels in milk; M/P ratio ~3.6 (relative infant dose 1.7–6.3% of maternal weight-adjusted dose). Monitor infant for drowsiness, respiratory depression. Use lowest effective dose, shortest duration.
Due to increased plasma volume and renal clearance in pregnancy, lower serum concentrations may occur. However, no specific dosing adjustments are recommended due to lack of data; use lowest effective dose for shortest duration. Avoid in third trimester if possible.
Acetaminophen: No dose adjustment needed; use lowest effective dose. Oxycodone: Pharmacokinetic changes in pregnancy include increased clearance (due to enhanced hepatic metabolism and renal blood flow) and increased volume of distribution, potentially reducing plasma concentrations. Dose may need to be increased (monitor for efficacy and avoid withdrawal); however, use lowest effective dose to minimize neonatal risks. Consider non-opioid alternatives.
Combination analgesic with opioid and non-opioid components. Hepatotoxicity risk from aspirin in children and adolescents (Reye syndrome). Measure serum salicylate and acetaminophen levels in overdose, but codeine is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy while ultra-rapid metabolizers risk toxicity. Avoid in patients with G6PD deficiency (aspirin-induced hemolysis). Caffeine may potentiate analgesia but also cause CNS stimulation and dependence. Prescribe with caution in elderly due to fall risk.
Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen intake should not exceed 4000 mg. Oxycodone has high abuse potential; consider prescribing naloxone for patients at risk of opioid overdose. Avoid concurrent use of other CNS depressants. Use with caution in elderly or renally impaired patients.
This medication contains codeine, which can be habit-forming; use only as prescribed.,Do not take with other products containing acetaminophen, aspirin, or caffeine.,Avoid alcohol; may increase risk of liver damage and sedation.,Stop use and seek medical attention if you experience ringing in ears, severe nausea/vomiting, or signs of Reye syndrome (children).,Do not drive or operate machinery until you know how this drug affects you.,Keep out of reach of children; accidental overdose may be fatal.
Do not exceed 4000 mg of acetaminophen per day from all sources.,This medication can cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking this medication.,Take exactly as prescribed; do not crush, chew, or break extended-release tablets.,Store securely out of reach of children and dispose of unused medication properly.,Seek emergency medical attention if you experience difficulty breathing, severe drowsiness, or signs of an allergic reaction.
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Agomelatine, a melatonergic antidepressant, combined with butalbital, a barbiturate and central nervous system (CNS) depressant, leads to additive CNS depression. This interaction increases the risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential overdose. Concurrent use may also alter hepatic metabolism via cytochrome P450 induction, reducing agomelatine efficacy and increasing butalbital toxicity."
"Amobarbital and Butalbital are both barbiturates that act as central nervous system (CNS) depressants. When co-administered, they exhibit additive CNS depression, leading to synergistic sedative and hypnotic effects, which can result in excessive sedation, respiratory depression, coma, or death. The combination significantly increases the risk of severe adverse outcomes, particularly in patients with compromised respiratory function or those taking other CNS depressants."
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE, answered by our medical review team.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is: 1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.. The standard adult dose of ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is: 1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Oxycodone is combined with Butalbital. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is classified as Category D/X. First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some st. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.